Xiang M, et al. - In this study including patients with FIGO stages I–III serous or clear cell uterine carcinoma who had at least total hysterectomy, the outcomes of adjuvant therapy were assessed. A total of 1,789 patients (1,437 serous, 352 clear cell) were identified in SEER-Medicare. Using SEER fields and Medicare claims, adjuvant external beam radiation, brachytherapy, and chemotherapy were determined. The outcomes of interest was death from endometrial cancer (cancer-specific mortality [CSM]) assessed using Gray's test (univariable analysis, UVA) and Fine-Gray regression (multivariable analysis, MVA). Findings revealed benefits of brachytherapy in stages I–II serous/clear cell cancers. Chemotherapy was found beneficial for stage III serous/clear cell cancers. Both treatments benefited patients with stages I–II serous cancers. The 4-year CSM for stages I–II serous cancers was 25% without brachytherapy or chemotherapy, 15% with one, and 9% with both. Lymph node dissection was performed in most of the cases (81%), which predicted lower CSM in stage III but not stages I–II patients.